| Regulatory Rapporteur September 2018 | MEMBERS |
| Using professional development to attract and retain talent | MEMBERS |
| Why professional development is more important than ever in regulatory affairs | MEMBERS |
| Deconstructing the revised EMA guideline on manufacture of the finished dosage f | MEMBERS |
| Where does drug substance manufacture end and drug product manufacture begin? | MEMBERS |
| FDA/EMA-triggered paediatric studies: Do they really advance child health? | MEMBERS |
| Accelerated pathways: CMC considerations | MEMBERS |